Bacterial Strain Composition for Enterochromaffin Cell and Cortisol Regulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a bacterial strain composition that can effectively increase enterochromaffin cell number and reduce cortisol levels to alleviate anxiety and stress-related symptoms, as existing treatments like fluoxetine have limited efficacy.

Innovation Solution

A combination of Bifidobacterium breve CCFM1025, Lactobacillus plantarum LPL28, and Lactobacillus acidophilus TYCA06 strains, administered orally, synergistically enhances enterochromaffin cell number and reduces cortisol levels, improving mood regulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments like fluoxetine are used, then anxiety and depression symptoms are treated, but efficacy is limited

Engineering Contradiction:

Improvetreatment efficacyVSAvoidlimited efficacy

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces probiotics (Lactobacillus plantarum and Bifidobacterium breve) as intermediary substances that act on the gut-brain axis to modulate the HPA axis and reduce cortisol levels. These probiotics serve as mediators between the gut microbiota and the central nervous system, providing an alternative pathway for treating anxiety and depression that complements or enhances the effect of conventional medications like fluoxetine.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter from direct central nervous system action (fluoxetine) to gut microbiota modulation (probiotics). By administering specific probiotic strains, the patent alters the composition and function of gut microbiota, which in turn affects serotonin synthesis and HPA axis regulation, thereby changing the physiological parameters related to stress response and mood regulation.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If cortisol level increases to facilitate stress response, then appropriate stress response is enabled, but anxiety and tension arise

Engineering Contradiction:

Improvestress response capabilityVSAvoidanxiety and tension

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes the feedback mechanism of the gut-brain axis to regulate cortisol levels. Probiotics administered to the gut modify the gut microbiota composition, which then sends signals back to the brain through the vagus nerve and other pathways, ultimately feedback-regulating the HPA axis and cortisol secretion. This creates a self-regulating system that maintains stress response capability while preventing excessive cortisol-induced anxiety.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent converts the potentially harmful effect of elevated cortisol (anxiety and tension) into a beneficial outcome by using probiotics to modulate the gut-brain axis. The probiotics transform the stress response pathway, converting excessive cortisol secretion into a balanced stress response that maintains adaptability without causing harmful anxiety symptoms.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If serotonin level declines, then emotional stability is affected, but increasing enterochromaffin cell number can restore serotonin synthesis

Engineering Contradiction:

Improveemotional stabilityVSAvoidserotonin level

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by administering probiotics that pre-establish a favorable gut microbiota composition before serotonin depletion occurs or early in the process. The probiotics (Lactobacillus plantarum and Bifidobacterium breve) preliminarily enhance enterochromaffin cell activity and serotonin synthesis capacity, creating a reservoir of serotonin production capability that can prevent or correct serotonin decline and maintain emotional stability.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250262256A1Bacterial strain composition for increasing enterochromaffin cell number and reducing cortisol level

Publication Date: 2025.08.21 GLACT BIOTECH

AI summary

The present invention provides a bacterial strain composition for increasing enterochromaffin cell number and reducing cortisol level, which comprises: a Bifidobacterium breve CCFM1025 strain, a Lactobacillus plantarum LPL28 strain, and a Lactobacillus acidophilus TYCA06 strain; wherein the CCFM1025 strain is deposited at the Guangdong Microbial Culture Center with a deposition number of GDMCC 60386; the LPL28 strain is deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 17954; the TYCA06 strain is deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 15210.